Marshall Fordyce Sells 17,500 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 17,500 shares of the company's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $46.94, for a total value of $821,450.00. Following the sale, the chief executive officer now owns 85,942 shares of the company's stock, valued at approximately $4,034,117.48. This represents a 16.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, October 23rd, Marshall Fordyce sold 19,375 shares of Vera Therapeutics stock. The stock was sold at an average price of $40.39, for a total value of $782,556.25.
• On Wednesday, October 9th, Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock. The stock was sold at an average price of $38.24, for a total value of $597,500.00.
• On Wednesday, September 25th, Marshall Fordyce sold 23,125 shares of Vera Therapeutics stock. The stock was sold at an average price of $46.05, for a total value of $1,064,906.25.

Vera Therapeutics Trading Down 2.3 %

NASDAQ:VERA traded down $1.06 on Friday, hitting $44.05. The stock had a trading volume of 540,987 shares, compared to its average volume of 875,890. The business's fifty day moving average is $44.94 and its 200 day moving average is $40.27. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics, Inc. has a 52 week low of $14.08 and a 52 week high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.21). On average, sell-side analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of VERA. Cetera Advisors LLC bought a new stake in Vera Therapeutics during the first quarter worth $235,000. William Marsh Rice University bought a new stake in Vera Therapeutics during the second quarter valued at $593,000. EFG Asset Management North America Corp. boosted its stake in Vera Therapeutics by 204.0% during the second quarter. EFG Asset Management North America Corp. now owns 31,444 shares of the company's stock valued at $1,137,000 after buying an additional 21,101 shares during the period. Bank of New York Mellon Corp boosted its stake in Vera Therapeutics by 6.3% during the second quarter. Bank of New York Mellon Corp now owns 165,322 shares of the company's stock valued at $5,981,000 after buying an additional 9,854 shares during the period. Finally, Legato Capital Management LLC bought a new stake in Vera Therapeutics during the second quarter worth about $273,000. Institutional investors own 99.21% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wells Fargo & Company assumed coverage on Vera Therapeutics in a research note on Thursday, November 21st. They issued an "overweight" rating and a $70.00 price target for the company. Guggenheim increased their price target on Vera Therapeutics from $56.00 to $64.00 and gave the company a "buy" rating in a research note on Monday, October 28th. JPMorgan Chase & Co. raised their target price on Vera Therapeutics from $72.00 to $75.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Wedbush raised their target price on Vera Therapeutics from $30.00 to $38.00 and gave the stock a "neutral" rating in a research note on Friday, November 8th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $107.00 target price on shares of Vera Therapeutics in a research note on Tuesday, October 1st. One analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $59.22.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.